The pooled findings highlight the uncertainty surrounding most reported outcomes, including knowledge, decisional conflict, anxiety, trial participation and attrition. There was very low quality evidence that decision aids lower levels of decisional regret to a small degree (MD -5.53, 95% CI -10.29 to -0.76). No data were identified on several prespecified primary outcomes, including accurate risk perception, values-based decision, or whether potential participants recognised that a decision needed to be made, were able to identify features of options that matter most to individuals, or were involved in the decision.
Authors' conclusions
There was insufficient evidence to determine whether decision aids to support the informed consent process for clinical trials are more effective than standard information. Additional well designed, adequately powered clinical trials in more diverse clinical and social populations are needed to strengthen the results of this review. More generally, future research on which outcomes are most relevant for assessment in this context would be helpful.
P L A I N L A N G U A G E S U M M A R Y

Decision aids for people deciding about taking part in clinical trials
We reviewed the evidence about the effect of specific tools, called decision aids, which aim to improve decision making in the informed consent process for people who are considering participating in a clinical trial. These tools were compared to the standard process used for informed consent in clinical trials. There is currently not enough evidence to draw conclusions about the effectiveness of decision aids in the informed consent process for clinical trials.
In clinical trials, one healthcare treatment is compared to another treatment or to no treatment. Before potential participants sign a consent form where they agree to take part in a clinical trial they must be given information about what will be expected of them and what they can expect. Research has shown that this information is often not as good as it could be. For example, people often misunderstand the information they have been given. Decision aids, which are tools that assist people to think about what matters most to them, support decision making for treatment and screening. Presenting information about trial participation through decision aids might improve the informed consent process by improving participants' knowledge, certainty with the decision and enabling them to consider what matters most to them personally.
We searched the literature for studies where potential trial participants were randomly allocated to receive decision aids, compared to no decision aids or to other types of information for informed consent. We found one study, which reported data from two separate decision aid trials, where people who were given a decision aid alongside standard information were compared to people who were given standard information alone. When data from these two trials were combined, the results were inconclusive and not able to show whether people given the decision aid had any more or less knowledge or uncertainty about their decision, or were more or less likely to participate in a trial, than the people who were only given standard information. However, people who used the decision aid may have felt less regret about their decision. Overall there was very low quality evidence to support these findings, which means that there may be uncertainty around the results, and therefore, further research is required.
The m ean knowledge in the intervention groups was 1.68 higher (1.91 
B A C K G R O U N D Description of the condition
A clinical trial is an experiment in which two or more interventions, possibly including a control intervention or no intervention, are compared by being (often randomly) allocated to participants. Clinical trials, and RCTs in particular, are considered the gold standard research methodology for rigorously evaluating the effectiveness of healthcare interventions (Pocock 1983). Increasingly, clinical trials are used to inform and direct clinical practice, and they constitute a significant component of publicly-funded research. However, evidence from publicly-funded trials has shown that approximately 70% of clinical trials fail to recruit their desired number of participants (Campbell 2007) . Failure to recruit the required sample size can lead to trials being underpowered which may not allow the effects of different interventions to be detected or accurately determined. To determine whether an intervention meets minimum criteria for classification as a decision aid, we assessed all interventions from potentially eligible studies using the International Patient Decision Aid Standards instrument (IPDASi) (Elwyn 2009b). This enabled us to determine whether the identified interventions could be considered decision aids (by containing all of the qualifying content items) rather than other educational interventions (which do not meet the minimum content requirements).The IPDASi instrument was developed to assess the quality of decision aids and contains a checklist of key qualifying items, under broad domains, to be included in such an intervention, that is, assesses key quality requirements and creates a minimum criteria threshold. For example, some of these domains cover provision of information about options in sufficient detail for making a specific decision; presentation of outcome probabilities; ways to clarify and express values; and structured guidance in deliberation and communication. The original application of this tool was to assess the quality of decision aids (through generation of a scoring system). However, in this instance we used the IPDASi tool to evaluate the qualifying items of interventions. The IPDASi tool has been updated recently, and now contains a cut-off score for determining whether or not an intervention is a decision support intervention that assesses key qualifying requirements and creates a minimum criteria threshold (Joseph-Williams 2013).
Evaluations of different methods of trial recruitment almost invariably occur as subsidiary studies to larger clinical trials. For example, investigators conducting a trial of two different surgical procedures for a given condition may be interested in understanding whether a decision aid helps to inform participation in said surgical trial. For clarity, throughout this review we used the term decision aid trial to refer to these subsidiary nested studies that were the focus of this review, and used the term parent trial to refer to the (often clinically focused, such as the comparison of surgical techniques in the above example) clinical trial in which they are set. 2014). This may be considered a negative outcome as it could result in trials taking longer to recruit their desired sample size, and impact on cost and time to report, which may mean that implementation of more effective interventions takes longer. However, inadequately informed participation in a clinical trial may result in participants dropping out of the trial at a later stage, or worse, participating in a trial that they might not have chosen had they been better prepared for the trial decision. Therefore, both outcomes of participation and withdrawal could be beneficial or harmful to a participant, depending on the specific trial.
How the intervention might work
Why it is important to do this review
Whilst use of decision aids within a trial context is relatively novel, the decision support literature is more mature, with international standards on best practice for use of decision aids (Elwyn 2006). Furthermore, there is now increased discussion in the ethics literature about the outcome of consent for research in the face of increasing regulatory requirements. Consideration is being given to other models for informed consent for research, of which decision aids are one. Therefore, it is timely to review these interventions in this context.
O B J E C T I V E S
To assess the effects of decision aids compared with no intervention, usual care, alternative interventions or a combination of these in people making decisions about participation in RCTs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs and quasi-RCTs of decision aids (i.e. decision aid trials) for informed consent for participation in a parent RCT were eligible for inclusion. We used the terms decision aid trial to refer to the subsidiary nested studies that were the focus of this review, and parent trial to refer to the (often clinically focused) clinical trial in which they are set. The decision may relate to participating in a real or hypothetical parent trial. We investigated studies in which the decision to participate in the trial was a hypothetical decision, so as to provide a comparison between real and hypothetical decisions in this context. Quasi-RCTs were defined as trials where randomisation was attempted but subject to potential manipulation or confounding, for example using day of week, date of birth or sequence of entry into trial.
Types of participants
We included potential clinical trial participants, or guardians of or proxy decision makers for potential trial participants. The term guardian in this review was used to mean parents or other guardians acting on behalf of their children, and guardians of adults who were unable to consent for themselves. There were no restrictions by age, gender, ethnicity or health condition of participants.
Types of interventions
Adhering to our protocol (Gillies 2012a ), included studies evaluated the use of decision aids in the informed consent process for clinical trials. Decision aids may vary in the type of support they provide and their specific aims. However, in general they are tools designed to prepare patients to participate in making specific and deliberative informed choices about their health care, including participation in clinical trials. These decision aids differ from standard patient information leaflets used in trial contexts, as in addition to providing evidence-based information about a health condition and identifying the options and outcomes, associated benefits, harms, probabilities, and scientific uncertainties, they: 1. help potential RCT participants to identify the valuessensitive nature of the decision and to clarify, either implicitly or explicitly, the value they place on the benefits, harms, and scientific uncertainties; 2. provide structured guidance in the steps of decision making; and 3. assist potential RCT participants in communicating about the decision and their values with others involved (e.g. clinician, family, friends) (Stacey 2014). We assessed all interventions from included studies for inclusion using the IPDASi (Elwyn 2009b). Two authors independently assessed the content of interventions from included studies using the IPDASi. The authors discussed their results and, if required, a third author repeated the process to enable consensus to be reached. The following interventions were excluded from this review:
• decision aids about screening or treatment decisions that were not set within the context of making a decision about participating in a parent RCT;
• any interventions that were not decision aids (as determined by the IPDASi) that aimed to enhance the informed consent process;
• any interventions designed only to improve communication (i.e. not focus on the decision process) about trial participation between health professionals and patients;
• studies that did not meet the minimum criteria for the intervention to be defined as a decision aid (Elwyn 2009b).
Included studies compared an intervention to: no intervention; standard information (usual care); alternative interventions (an adapted version of the intervention, such as a more concise version of the comparator intervention, or a change in mode of delivery (audio versus paper)); or a combination of these.
Types of outcome measures
In line with previously published reviews of treatment and screening decision aids, and reviews of information considered important for participation in RCTs (Flory 2004; Synnot 2014 Stacey 2014), we considered the outcomes listed below as important. We also included any relevant studies that met the inclusion criteria but that included outcomes other than those specified.
Primary outcomes
Evaluation of informed choice
• Knowledge or understanding;
• Accurate risk perception;
• Values-based decision;
• Recognition that a decision needs to be made; • Ability to identify features of options that matter most to individuals;
• Involvement in decision.
Decision-making process measures
• Decisional conflict: personal uncertainty about which course of action to take when faced with a choice between competing options. Conflict can be measured using the Decision Conflict Scale (DCS) and is most often measured at the point of decision making i.e. contemporaneously (O'Connor 1995);
• Decision regret: healthcare decisions that result in bad outcomes can lead to regret, which can subsequently affect decision making. Regret can be measured using the Decision Regret Scale and is most often measured after a decision has been made i.e. retrospectively (Brehaut 2003) .
Secondary outcomes
We collected data on the following secondary outcomes relating to the parent RCT that people were being recruited to:
• Participation (willingness to participate, or participation rate);
• Attrition.
Other secondary outcomes related to the decision support RCT were:
• Anxiety;
• Cost of intervention;
• Patient-recruiter communication.
Search methods for identification of studies Electronic searches
In March 2015 we searched the following databases:
• Cochrane Central Register of Controlled Trials (CENTRAL);
• The strategies for each of the databases are presented in Appendix 1. There were no language or date restrictions.
To identify ongoing clinical trials, the following registers were also searched:
• WHO International Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/);
• ClinicalTrials.gov;
• ISRCTN Register (http://www.controlled-trials.com/isrctn/ ).
Searching other resources Grey literature
We searched grey literature using ProQuest Dissertations to access digital dissertations and theses that were relevant to this review.
Reference lists
We searched reference lists of included studies and relevant review articles.
Handsearching
We handsearched journals that frequently publish articles on decision aids, such 
Correspondence
We contacted the shared decision making community through social media to identify any additional new or ongoing studies. We also contacted Directors of UKCRC Clinical Trials Units to identify any new or ongoing studies. In addition, when authors of included studies were contacted for further details of interventions we also asked if they were aware of any additional studies in this area. No studies were identified through these routes. Two ongoing studies (see Characteristics of ongoing studies) were identified.
Data collection and analysis
Selection of studies Stage 1
We conducted searches for relevant studies on the prespecified databases. We combined results and removed duplicates.
Stage 2
All review authors independently screened titles and abstracts of identified articles for relevance. Sets of abstracts were created such that all identified articles were screened by two authors.
Stage 3
Four authors (KG, ZS, SC, JB) further assessed the set of potentially relevant abstracts identified from the initial full screen and discussed any disagreements. We retrieved full text copies for all potentially relevant papers, including those where the description (usually relating to the intervention) was insufficient to make a decision about inclusion.
Stage 4
Two authors independently screened the full text articles against eligibility criteria for inclusion or exclusion. Where interventions were deemed eligible, authors assessed interventions using the IPDASi, as per the process outlined by Elwyn 2009b and Joseph-Williams 2013. Two review authors discussed results, and if required, a third researcher repeated the process to enable consensus to be reached. See Characteristics of excluded studies for details on reasons for exclusion of full text articles. We provided citation details and any available information about ongoing studies (see Characteristics of ongoing studies), and collated and reported details of duplicate publications, so that each study was the unit of interest in the review. We reported the screening and selection process in an adapted PRISMA flow chart 
Data extraction and management
Four authors (KG, ZS, SC, JB) independently extracted data from each included study. Any discrepancies were resolved by discussion to reach consensus, or through consultation with a third author where necessary. We based data extraction categories on the Cochrane Consumers and Communication Group Data Extraction Template but supplemented those with additional important categories for this context (relating to parent RCT), and included the following categories: features of the parent RCT; decision support RCT methods; intervention and comparator features; outcomes; data and results; conclusions and limitations. All extracted data were entered into RevMan (RevMan 5.3) by one review author, and checked for accuracy against the data extraction sheets by a second review author working independently. Information is presented in Characteristics of included studies. When more than one primary outcome was available from an included study (e.g. when multiple outcomes contribute to a single category, such as knowledge and understanding) we used the following process for selecting a single outcome (Brennan 2009):
1. Select the primary outcome that was identified by the authors of the included study;
2. When no primary outcome was identified, select the outcome specified in the sample size calculation;
3. If there were no sample size calculations, we ranked the effect estimates and used the median effect estimate.
Assessment of risk of bias in included studies
We assessed and reported the risk of bias of included studies in accordance with the Cochrane Handbook (Higgins 2011) and the guidelines of the Cochrane Consumers and Communication Group (Ryan 2011), which recommends reporting the following items for RCTs based on the risk of bias tool:
• random sequence generation;
• allocation concealment;
• blinding (participants, personnel);
• blinding (outcome assessors);
• completeness of outcome data;
• selective outcome reporting;
• baseline comparability (for quasi-randomised studies).
Four authors (KG, ZS, SC, JB) independently assessed risk of bias of the included study, rating each of the domains as high risk, unclear or low risk (as detailed in the Cochrane Handbook), with any disagreements being resolved through discussion and consensus.
Our assessment is reported in Risk of bias in included studies, along with a justification for the ratings given. Whilst we had planned to consider the results from the risk of bias assessment of included studies when performing and presenting analyses, and restricting the primary analysis to studies at low risk of bias, this was not appropriate due to inclusion of a small number of studies in the analysis.
The results of the risk of bias assessment have been incorporated into the review through standard tables, and systematic narrative description and commentary about each of the elements, leading to an overall assessment the risk of bias of included studies and a judgement about the internal validity of the reviews results. Studies were deemed to be at the highest risk of bias if they are scored as at high or unclear risk of bias for either the sequence generation or allocation concealment domains, based on growing empirical evidence that these factors are particularly important potential sources of bias (Higgins 2011).
Measures of treatment effect
A meta-analysis was conducted. It should be highlighted that whilst only one study was included, it reported data from two decision aid trials (Juraskova 2014 (Prevention); Juraskova 2014 (DCIS)). The data were presented separately in the original publication (patients were being recruited to two separate parent trials and as such generated two separate decision aid trials) but it was felt to be appropriate to pool the results for this review (see justification in Included studies). The included study had several continuous outcomes. Therefore, we analysed data based on the mean, standard deviation (SD) and number of people assessed for both the intervention and comparison groups to calculate a mean difference (MD), with 95% confidence interval (CI), between the post-intervention values of the randomised groups. For dichotomous outcomes we analysed data based on numbers of events and numbers of people assessed in the intervention and comparison groups, and used these to calculate a risk ratio (RR) with 95% CI.
Unit of analysis issues
We analysed both the mean and SD provided in the included study. We calculated the mean and SD according to the overall numbers within each arm using established approaches (Higgins 2011). If cluster-RCTs were included we would have checked for unitof-analysis errors. If errors were found, and sufficient information was available, we would have re-analysed the data using the appropriate unit of analysis, by taking account of the intra-cluster correlation (ICC). We would have obtained estimates of the ICC by contacting authors of included studies, or imputing them by using estimates from external sources. If it was not possible to obtain sufficient information to re-analyse the data we would report effect estimates and annotate unit-of-analysis error.
Dealing with missing data
We contacted study authors to obtain missing data (participant, outcome, or summary data). For participant data, we analysed outcomes as reported as no information on intention-to-treat was available within the study report or was available from authors of the study. We reported on the levels of loss to follow-up and assessed this as a source of potential bias. Where possible, missing standard deviations were calculated from other reported statistics. Specifically, this was the case for percentage enrolled and percentage who dropped out. We discussed any impact of missing data on the findings of the review in the main text and the Risk of bias in included studies table.
Assessment of heterogeneity
Where studies were considered similar enough (based on consideration of populations and/or interventions) to enable pooling of data using meta-analysis, we assessed the degree of heterogeneity by visual inspection of forest plots. We assessed heterogeneity between the decision aid trials from the included study using the Chi² statistic, to provide evidence of heterogeneity, and the I² statistic, to quantify the degree of heterogeneity (a Chi² P value of less than 0.10 or an I² value equal to or more than 50% was considered to indicate substantial heterogeneity).
Where heterogeneity was present in pooled effect estimates we planned to explore possible reasons for variability by conducting subgroup analysis.
We planned that where we detected substantial clinical, methodological or statistical heterogeneity across included studies we would not report pooled results from meta-analysis but instead use a narrative approach to data synthesis. In this event, we planned to attempt to explore possible clinical or methodological reasons for this variation by grouping studies that were similar in terms of populations, interventions and methodological differences (such as real or hypothetical decision) to explore differences in intervention effects. However, the small number of included studies meant that subgroup analyses could not be conducted.
Assessment of reporting biases
We planned to assess reporting bias qualitatively based on the characteristics of the included studies (such as if only small studies indicating positive findings were identified for inclusion), and if information that we could obtain from contacting experts and authors of studies suggested that there were relevant unpublished studies. If we had identified sufficient studies (at least 10) for inclusion we would have constructed a funnel plot to investigate small study effects, which may have indicated the presence of publication bias. We would have formally tested for funnel plot asymmetry, with the choice of test made based on advice in Higgins 2011, and bearing in mind that there may be several reasons for funnel plot asymmetry when interpreting the results.
However, we could not conduct assessment of reporting bias due to only one study being eligible for inclusion, but this was not deemed to be a considerable risk.
Data synthesis
There was only one included study, presented as two separate decision aid trials, with no difference in the comparator groups. In future updates we will analyse studies according to comparison groups, specifically:
• Decision aid versus no intervention;
• Decision aid versus usual practice;
• Decision aid versus alternative interventions.
We conducted a meta-analysis where trial data were sufficiently similar (in intervention, outcome measure, length of follow-up and type of analysis). We present results for each of the reported outcomes, organised by the comparison intervention. Due to the variability in both the populations and interventions of the included study, we used a random-effects model for metaanalysis.
We did not use narrative synthesis, but would do in future updates where studies are not suitable for meta-analysis. For example, if mean and SD cannot be extracted for continuous outcomes, we will present the summary statistic and measure of variance at follow-up available in the text of the included studies, and if there is more than one study, we will present these data in additional tables.
Subgroup analysis and investigation of heterogeneity
We found there were insufficient data to conduct subgroup analysis. In future updates we will conduct subgroup analyses where data are available, according to:
• Decision regarding trial participation: real versus hypothetical;
• Mode of delivery (e.g. video/computer versus audio/ pamphlet). Mode of delivery may make a difference to the effectiveness of decision support tools. For example, an RCT that compared a paper-based decision aid versus an Internet-based version for prostatic specific antigen (PSA) screening showed that participants randomised to the Internet version had different levels of screening uptake (Evans 2010). This may translate to different modes of delivery affecting uptake to clinical trials, and as such, this would be explored in subgroup analysis;
• Context of intervention delivery. Context of intervention delivery is also linked to mode of delivery but may impact more on cost effectiveness of the intervention (Belkora 2010). Moreover, context has been proposed by other researchers in the decision aid literature as being an important variable for consideration during decision aid development, delivery and evaluation (Elwyn 2010a, Thomson 2010). The following contexts will be explored in subgroup analysis:
• used in face-to-face clinical encounters; • used independently from the clinical encounter;
• Quality of intervention as measured by the IPDASi (dichotomised by score: 0 to 50 and 51 to 100);
• Participant characteristics. Various participant characteristics may have an impact on the effectiveness of decision aids. Age and gender have been shown to have a significant effect on participants' perception of the factors that determine decision processes (Sanz de Acedo Lizararraga 2007). Also, decision aids designed specifically for use with low level literacy groups have been shown to be effective in supporting informed choices and greater participant involvement in some screening decisions (Smith 2010). As such, the following would be explored in subgroup analysis:
• age (categorised as under 18, 18 to 65, over 65 years);
• gender (male versus female);
• education (no formal education and higher education).
Sensitivity analysis
Because there was only one included study, which included two methodologically similar decision aid trials which did not fulfil the high/unclear risk of bias requirements outlined below, we were unable to conduct a sensitivity analysis. In future updates, we will group studies according to whether they are at high/unclear risk of bias or low risk of bias to investigate the effect of trial quality on meta-analysis results. We will categorise studies at overall high or unclear risk of bias if rated as being at high or unclear in one or more of the following domains: sequence generation, allocation concealment or selective outcome reporting. The remaining studies would be considered at low risk of bias. These three domains were selected because limited, but growing, empirical evidence from methodological studies suggests they can most strongly influence intervention effect estimates (Higgins 2011). We will exclude studies at high/unclear risk of bias in a sensitivity analysis to determine whether the risk of bias influenced review findings.
Assessing the overall quality of the evidence
We used the GRADE approach to make assessments of the overall quality of the evidence for each outcome on each of the following domains: risk of bias, inconsistency, imprecision, indirectness and publication bias. We downgraded a starting rating of high quality evidence by one level for serious concerns (or by two levels for very serious concerns) about each of these domains. We considered the impact of the following factors (as specified by Higgins 2011) on the quality of the evidence:
• risk of bias: limitations in the design (e.g. lack of allocation concealment, lack of blinding, large loss to follow up, etc.) and implementation of included studies;
• inconsistency: unexplained heterogeneity or inconsistency of results;
• imprecision: imprecise results, that is, wide confidence intervals generated from small samples and few events;
• indirectness: where the included evidence is from indirect populations, interventions, controls or outcomes;
• publication bias: probability of publication bias.
Each quality domain was assessed and where there was a low risk of bias the quality rating remained high, an unclear risk of bias resulted in a downgrading of the evidence by one level and a high risk of bias by two levels for very serious concerns. The judgements regarding downgrading were guided by Table12.2d in the Cochrane Handbook (Higgins 2011). Two authors independently assessed the quality of the evidence as implemented and described in the GRADEprofiler (GRADEpro) software (Schünemann 2011).
Summary of findings table
We used the GRADE criteria to evaluate quality of evidence using GRADEprofiler (GRADEPro) software (Schünemann 2011) before presenting data in a summary of findings table and taking into account the quality of the evidence, magnitude of the effect of the intervention and the sum of the available data on the primary rather than main outcomes, as outlined in Types of outcome measures. We presented outcomes in the summary of findings table in terms of: 1. Evaluation of informed choice (knowledge; accurate risk perception; values-based decision; recognition that a decision needs to be made; involvement in decision); and 2. Decision making process measures (decisional conflict and decisional regret). We provide a source and rationale for each assumed risk cited in the table. Because GRADE allows only seven outcomes to be listed in the summary of findings table, a primary outcome (ability to identify features of options that matter most to individuals) was not included. Our justification was that we felt this outcome may overlap with 'values based decision' outcome. It should be noted that this was a post-hoc decision.
Consumer participation
As part of a larger project (led by KG), a survey and interviews with RCT stakeholders, which included potential participants, clinicians, and trialists, was conducted to determine key information to include in, and perceptions of, a decision aid to inform RCT participation (Gillies 2013; Gillies 2014b ). This stakeholder consultation stage helped to identify consumer-relevant content of these interventions and relevant outcomes, which mapped on to the decision aids identified in this review. The first author (KG) is leading additional work to identify a core outcome set for evaluation of interventions to improve informed consent (Gillies 2014e) . This work will inform future updates of this review.
R E S U L T S Description of studies
See Characteristics of included studies; Characteristics of excluded studies; and Characteristics of ongoing studies.
Results of the search
and subsequently excluded five of these (see Characteristics of excluded studies and Excluded studies) . There was one paper that reported two decision aid trials which met the inclusion criteria (Juraskova 2014 (Prevention); Juraskova 2014 (DCIS)). Figure 1 illustrates the searching and screening process.
Included studies
We included one study that presented data from 290 women who participated in two separate decision aid trials (Juraskova 2014 (DCIS); Juraskova 2014 (Prevention)). These women were considering participation in one of two parent RCTs -either the International Breast Cancer Intervention Study II (IBIS-II) Prevention Trial (a primary prevention trial comparing anastrozole or placebo in postmenopausal women at high risk of breast cancer) or the IBIS-II Ductal Carcinoma in Situ (DCIS) Trial (a treatment trial comparing anastrozole or tamoxifen in postmenopausal women who had previous surgery for DCIS) (Cuzick 2008). The authors of the decision aid trials reported the nested setting as being within two separate parent RCTs and presented the data analysis separately for each decision aid trial. Outcomes measured (both content and timing) were identical across both decision aid trials. For the purposes of this review we have also treated the decision aid trials as two individual trials. This is for several reasons, not least because the study authors treated the decision aid trials as two separate clinical trials, but in addition:
• the parent trials to which participants were being recruited were testing different clinical interventions in different populations and addressed different decisions about trial participation;
• the recruitment methods for each decision aid trial differed (e.g. the parent primary prevention trial identified women using media advertisements who were telephoned by clinical staff and invited to join the relevant decision aid trial; whereas women eligible for the parent treatment DCIS trial were approached directly by their surgeon and invited to join the relevant decision aid trial);
• the eligible populations included in the decision aid trials differed;
• the decision aid interventions tested in each decision aid trial differed.
For clarity, throughout the remainder of this review when referring to the decision aid trials collectively we refer to them as the decision aid trials and separately as:
• prevention decision aid trial when referring to the nested decision aid trial that recruited women to the IBIS-II parent primary prevention trial; and
• DCIS decision aid trial when referring to the nested decision aid trial that recruited women to the IBIS-II parent DCIS treatment trial.
Study design
Both decision aid trials nested in the included study were two-arm parallel RCTs.
Sample size
The randomised sample for the DCIS decision aid trial was 67 and 223 for the prevention decision aid trial. In total 290 people participated in the included study.
Setting
Participants were recruited via the parent trial sites which were largely based in high-income countries (Australia, New Zealand, and United Kingdom).
Participants
The women who participated in the decision aid trials were eligible for the parent trial, the IBIS-II, specifically, either the Prevention or DCIS trials. The population of participants recruited to both decision aid trials were very similar and included postmenopausal women with a mean age of 59 years. As per the parent trial, the recruitment approach differed by decision aid trial; the prevention decision aid trial women were invited by clinical staff over the telephone and the DCIS decision aid trial women were invited by their surgeon. It was explicit in the report of the included study that the interventions in both decision aid trials were conducted in English, with most (94%) women specifying English as their spoken language. Further information about the participants is presented in Characteristics of included studies.
Interventions
The included study reported two decision aid trials that were both two-arm parallel RCTs of a single comparison: decision aids versus standard informed consent procedures. The interventions in the decision aid trials were paper-based decision aids. These were compared to standard informed consent procedures, which included a patient information leaflet, but no further details about the control intervention were available. Two decision aids were tested, one specific to each of the clinical trials (one each for the prevention and DCIS decision aids trials). The delivery of the interventions was not clear but likely was without direct supervision and may have differed by decision aid trial (the prevention decision aid trial participants may have received the decision aid by post and the DCIS decision aid trial participants in a face-to-face setting). The decision aid booklets were designed to include evidence-based representation of breast cancer risk, the parent trial rationale, explanation of management options available on and off the trial, a comparison of the risks and benefits of each option, and values clarification worksheets. The decision aids were designed to meet IPDAS guidelines for content development.
Outcomes Primary outcomes Knowledge and understanding
Evaluation of informed choice
• Recognition that a decision needs to be made;
• Ability to identify features of options that matter most to individuals;
Decision-making process measures
The included study reported data for three different measures of knowledge:
• Knowledge of clinical trials (study specific seven item measure of general trial related knowledge);
• Objective knowledge (assessed using a 12 and 16 item study specific knowledge scale in the Prevention and DCIS cohorts respectively); and
• Subjective knowledge (assessed using Part B (14 items assessing subjective/perceived understanding) of the Quality of Informed Consent (QuIC) scale (Joffe 2001)).
Knowledge was measured at baseline (post-randomisation after a trial participation decision had been made -post-decision). As the decision aid trials did not rank knowledge outcomes, we chose to include only data collected with a validated tool, i.e. the QuIC measure of subjective/perceived understanding . This judgement was based on a hierarchy of measures which assumed validated objective measures to be superior to study-specific non-validated measures This hierarchical judgement relating to multiple measures of the same outcome was a post-hoc decision made during the review process. Decisional conflict was measured at baseline in the decision aid trials using the Decisional Conflict Scale (DCS), which contains 16 items that measure the amount of uncertainty an individual has about a course of action (O'Connor 1995). This was the primary outcome for the decision aid trials. Decision regret was measured at three months using the Decisional Regret Scale, a five-item scale with good internal consistency that measures regret associated with a decision made in the past (Brehaut 2003) . The decision aid trials did not report data for the following primary outcomes:
• accurate risk perception;
• values-based decision;
or if potential participants had:
• recognised that a decision needed to be made;
• ability to identify features of options that matter most to individuals;
• involvement in decision making.
Secondary outcomes
Data on secondary outcomes relating to the decision about entry into the parent trial were collected in the decision aid trials:
• participation (presented as both intention to participate and percentage actually enrolled in IBIS-II (parent trial), we included data captured using the second measure (% enrolled) as it is a more definitive measure of participation);
• attrition (as percentage who dropped out from IBIS-II (parent trial)); and
• anxiety (measured at baseline using a six-item short form of the State-Trait Anxiety Inventory (STAI-S) scale (Marteau 1992)).
No data were reported for:
• cost of intervention;
• patient-recruiter communication.
Consumer involvement
Although the decision aid trials did not report consumer involvement, an earlier linked publication described consumer involvement in the development of the decision aids tested in the prevention decision aid trial (Juraskova 2008).
Funding sources
The included study was supported by Susan G. Komen for the Cure (grant number BCTR0503961) and discretionary funding from the Breast Cancer Institute of Australia, which is the fundraising and education department of the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG; no grant number).
Excluded studies
We excluded 23 studies following assessment of full text articles. The reasons for excluding papers that went through full text review are outlined in the Characteristics of excluded studies. There were four reasons that contributed to studies being excluded. The most prevalent reason was the intervention not being a decision aid (determined by assessment of qualifying items using IPDASi) (n = 8), followed by the intervention not being a decision aid for trial participation (i.e. a decision aid for treatment or screening) (n = 5), or the intervention ineligibility was decided based on published report and/or information present in a similar Cochrane review (Synnot 2014) and/or discussion with study author (n = 7) and ineligible study design (n = 3).
Risk of bias in included studies
We assessed the two decision aid trials from one included study for risk of bias and assessed them to be at moderate to high risk of bias overall (Risk of bias in included studies; Figure 2 ; Figure  3 ). The included study provided insufficient information in the published paper about some aspects of study design and conduct and was assessed as unclear on a number of domains. Risk of bias was highest in the domains relating to blinding of participants and outcome assessors which reflects the inherent difficulties of blinding in trials testing information provision in this context. 
. Risk of bias summary: review authors' judgements about each risk of bias item for each included study
As all outcomes (for which data were identified) included pooled data from RCTs only, the evidence was downgraded from high to low quality for risk of bias, indirectness, imprecision or publication bias for all outcomes with the exception of attrition, which also included downgrading of the evidence (from high to low quality for inconsistency).
Allocation Random sequence generation
The authors of the included study reported using a randomisation sequence that was generated using a web-based random number generator (www.randomizer.org) with randomisation performed in blocks of 10 according to centre and was rated as low risk of bias.
Allocation concealment
A pre-randomised, sequentially numbered system using sealed envelopes was reported by the authors and assessed as being adequate allocation concealment at low risk of bias.
Blinding
Most outcomes measured in RCTs of this type capture self-reported outcomes often relating to knowledge and other aspects of decision making. As the participants are not blinded to their allocation, and they are the outcome assessors, it is indeed difficult for investigators to blind outcome assessment. Of all outcomes reported, only two could be measured objectively: actual enrolment and drop out from the parent RCT. The included study was assessed at being of high risk of bias for blinding of both participants and outcome assessment.
Incomplete outcome data
With regard to completeness of outcome data, the authors reported that 66 participants (23% of those randomised) were not included in the analysis (a post-randomisation decision) due to previous participation in a clinical trial which they hypothesise may have resulted in ceiling effects for several of the measures. In addition, data were only reported on 146 of the 290 randomised (50%) participants, bringing into question whether the participants for whom data were missing differed from those who did not. However, the authors reported that there were no differences in rates or reasons for dropout across the arms.
Selective reporting
The study did not refer to a published protocol against which the published report could be assessed. Risk of bias was therefore assessed to be unclear. However, of those outcomes listed in the methods all were presented in the results.
Other potential sources of bias
There were recruitment problems reported for the DCIS decision aid trial, which resulted in that trial being underpowered. Each of the reported decision aid trials required a sample size of 128 (64 per arm) to detect an effect size of 0.5 with 80% power. The DCIS decision aid trial randomised 67 participants and analysed data on 24, and the Prevention decision aid trial randomised 223 and analysed data on 95 participants (see Incomplete outcome data (attrition bias) for more information).
Effects of interventions
See: Summary of findings for the main comparison Decision aids for informed consent versus standard informed consent for people considering taking part in clinical trials
Decision aid for informed consent versus standard informed consent Primary outcomes
Knowledge
The included study reported three separate measures of knowledge for both decision aid trials (see Included studies). The data on subjective knowledge was selected for analysis of knowledge due to the fact that these data were collected using a validated tool (QuIC; Joffe 2001). The pooled intervention arms from the decision aid trials highlighted that effects on knowledge are uncertain, compared with standard informed consent procedures, given the wide confidence intervals and small sample sizes (MD 1.68, 95% CI -1.91 to 5.26; Analysis 1.1). There was no indication of heterogeneity in these results. The quality of the evidence was rated as very low due to risk of bias (a lack of blinding and incomplete outcome data), indirectness of populations studied, and the wide confidence intervals around the effect estimate, with at least 25% variation in both control and intervention groups.
Decision conflict
Pooling the decision conflict scores (a measure of uncertainty) for both decision aid trials also showed uncertain effects on decision conflict, compared with standard informed consent procedures, due to the wide confidence intervals and small sample size (MD 3.47, 95% CI -1.51 to 8.45; Analysis 1.2). Again there was no indication of heterogeneity in the results for this outcome.
As with the knowledge outcome, the quality of the evidence for decisional conflict was downgraded from high to very low due to risk of bias (a lack of blinding and incomplete outcome data), indirectness of populations studied, and the wide confidence intervals around the effect estimate, with at least 25% variation in both control and intervention groups.
Decision regret
The pooled intervention arms showed evidence of a small effect in favour of the decision aids on decisional regret, compared with standard consent procedures, when combining the results from both decision aid trials (MD -5.53, 95% CI -10.29 to -0.76; Analysis 1.3), again with no evidence of heterogeneity in the results. However, the data were from two relatively small decision aid trials, with the weighting of the evidence in favour of the larger prevention decision aid trial which had a significant effect estimate. The quality of the evidence was rated as very low due to risk of bias (a lack of blinding and incomplete outcome data), indirectness of populations studied, and the confidence intervals around the effect estimate being relatively large in relation to the effect size.
Secondary outcomes
Participation
Actual enrolment was measured as a percentage of those who participated in the parent trial. Following pooling of results across both decision aid trials there was uncertainty around any effect on enrolment, compared with standard consent procedures (RR 1.06, 95% CI 0.76 to 1.48; Analysis 1.4). There was no indication of heterogeneity in the results; but the quality of the evidence was rated as very low due to risk of bias (a lack of blinding and incomplete outcome data), indirectness of populations studied, and wide confidence intervals around the effect estimate.
Attrition
Attrition was reported as the number of participants who dropped out of the parent RCT who were enrolled in the decision aid trial. Results from the decision aid trials were pooled and showed uncertain effects on attrition, compared with standard consent procedures (RR 1.55, 95% CI 0.51 to 4.68; Analysis 1.5). As for other outcomes, there was no evidence of heterogeneity in this result; but the quality of the evidence was rated as very low due to risk of bias (a lack of blinding and incomplete outcome data), indirectness of populations studied, and wide confidence intervals around the effect estimate, with at least 25% variation of the events in both the control and intervention groups.
Anxiety
Uncertain effects were observed on anxiety when the results from the decision aid trials were pooled (MD -2.38, 95% CI -10.65 to 5.90; Analysis 1.6). There was substantial heterogeneity (I² = 78%) in this result, with both positive and negative effects on anxiety for the two different trials (but with confidence intervals that passed through the line of no effect). The quality of the evidence was again rated as very low due to risk of bias (a lack of blinding and incomplete outcome data), indirectness of populations studied, and wide confidence intervals around the effect estimate. No data were reported for the following prespecified primary outcomes: accurate risk perception; values based decision; recognition that a decision needs to be made; ability to identify features of options that matter most to individuals; or involvement in decision; or secondary outcomes of intervention cost or patient-recruiter communication.
D I S C U S S I O N
Summary of main results
We identified one study reporting two decision aid trials recruiting with a total of 290 participants that investigated the effectiveness of decision aids (compared to standard information) in the informed consent process for RCTs (Juraskova 2014 (Prevention); Juraskova 2014 (DCIS)). This study report included postmenopausal women being recruited to one of two decision aid trials, each nested within the context of a larger parent RCT, either the IBIS-II Prevention Trial (a prevention RCT comparing anastrozole or placebo in postmenopausal women at high risk of breast cancer) or the IBIS-II DCIS Trial (a treatment RCT comparing anastrozole or tamoxifen in postmenopausal women who had previous surgery for DCIS) (Cuzick 2008).
When the results from each of the individual decision aid trials were pooled, there was considerable uncertainty about the effects of the intervention, compared with standard information, on most of the outcomes reported: knowledge, decisional conflict, anxiety, trial participation and trial attrition, due to wide confidence intervals and small sample sizes. There was very low quality evidence that decision aids may decrease decisional regret to a small degree (i.e. less regret amongst those exposed to the intervention), when compared with standard information. Additional outcomes we identified as being of potential importance were not reported. These included accurate expectations about benefits and harms; reaching choices that are consistent with personal values; recognition that a decision needs to be made; and involvement in the decision.
Overall completeness and applicability of evidence Population and setting
Our conclusions were limited because only one study was identified (albeit including two decision aid trials) that met our inclusion criteria. The interventions investigated were delivered in high income countries to mainly English speaking postmenopausal women who had existing breast cancer or who were at high risk of developing breast cancer.
Control intervention
It was noteworthy that the included study compared decision aids with existing, written, consent documents and the intervention group received both. Other reviews of informed consent interventions (for trials (Synnot 2014) and treatment (Kinnersley 2013)) have highlighted the potential for both the intervention and control groups to benefit in studies of this type. We believe the results of the included study to be consistent with this finding for a number of reasons. Firstly, the authors note that the trial recruiters involved in the parent trial (IBIS-II) had received communication skills training, which may have influenced the results of the decision aid trials. Moreover, trial recruiters may have changed their behaviour during the decision aid trials, optimising their informed consent practice. Another potential limitation of the included study is the lack of detail about the fidelity of both the intervention and standard information. In other words, no information was recorded about whether the decision aids or the standard information was in fact read by participants. Trials of this kind may benefit from process evaluations to explore how trial processes and interventions are delivered in context.
Study design
Several full reviews (both published and in progress) have investigated the effectiveness of a variety of interventions in the informed consent process for clinical trials (Flory 2004; Hon 2012; Nishimura 2013; Synnot 2014). Whilst some of these studies focus on specific types of interventions (such as audio-visual interventions, Synnot 2014), others have reviewed all interventions and grouped them accordingly (Nishimura 2013). Interventions for informed consent vary significantly, from simplified consent forms to enhanced discussions involving directed training for staff (Nishimura 2013). However, many of these interventions focus more on the structure and content of the presented information rather than the process of decision making. Therefore, to focus our review we only included interventions that aimed to support an informed decision making process and these interventions were defined according to the IPDASi (Joseph-Williams 2013). This definition deviates from the method used in the review of treatment and screening decision aids, which defined interventions as decision aids if they were "designed to help people make specific and deliberative choices among options (including the status quo), by making the decision explicit and by providing (at the minimum) a) information on the options and outcomes relevant to a person's health status and b) implicit methods to clarify values" (Stacey 2014). Some of the interventions we excluded from our review (Abhyankar 2011; Meropol 2013; Tait 2010) contained components of decision aids but did not meet minimum criteria we defined as a requirement for inclusion based on those described by the IPDASi (Joseph-Williams 2013). In addition, some of these interventions were treatment decision aids being used alongside patient information leaflets (i.e. trial participation was not the index decision); and rather the decision to have treatment or not was the index decision (Eccles 2013). Future updates may wish to consider the inclusion of these studies (and others which may fit the definition used by Stacey 2014 in specific subgroups comparisons (i.e. values clarification exercises) or comparisons (i.e. treatment decision aid + patient information leaflet vs. patient information leaflet). The effect of excluding these studies on the results of this review is unclear.
Outcomes
As noted by other authors, the assessment and measurement of outcomes associated with informed consent is problematic (Kinnersley 2013; Synnot 2014; Nishimura 2013).The heterogeneity of outcome measures used to assess knowledge or understanding has significant implications for systematic reviews and meta-analysis of these types of outcome data. There is currently no standardised validated measure for knowledge or understanding as an outcome (Nishimura 2013). Neither is there consensus on whether this is an adequate measure of being informed, and when it should be measured in relation to the decision. This is an area requiring further research (Gillies 2012b; Gillies 2014c). We are currently conducting a systematic review of existing validated measures of informed consent, but again many of these measures focus on knowledge and understanding and are largely assessed through recall (Gillies 2014d ). There has also been debate in the literature about the adequacy of decisional regret as a measure of the decision making process, both in the context of treatment (Elwyn 2010b) and trial decisions (Gillies 2014c). Some opponents have argued that regret can be biased by decision outcomes (due to the timing of outcome measurement i.e. post-decision) and may not offer a measured representation of the decision process but more a judgement related to outcomes (Elwyn 2010b). When considering interventions aimed to improve the decision making process it is also important to consider outcomes in addition to knowledge and understanding. Whilst these outcomes are important building blocks for informed decision making they are not the only components that can help support patients' decisions (Stacey 2014). When determining our specified outcomes for this review we were informed by the Cochrane review on decision aids for treatment and screening, which considered decision making as two components: evaluation of informed choice (encompassing attributes of the decision and its process); and decision making process measures (Stacey 2014). Other authors of similar reviews have also highlighted the need for outcome measures that capture informed consent "as a unified concept" (Kinnersley 2013) and that more research is needed to gain consensus on defining the range of potentially relevant outcomes in this context, not just from a researcher's perspective, but also from patients (Synnot 2014). We are conducting research with a range of stakeholders (including patients) aimed to develop a core outcome set for the evaluation of interventions intended to improve informed consent for clinical trials (Gillies 2014e). Lastly, process measures associated with delivery of the intervention were prespecified in this review (e.g. patient-recruiter communication and costs of intervention) but not reported in the included study. Data from process measures would be helpful to make decisions about implementation of decision aids, especially where the evidence is equivocal.
Quality of the evidence
The evidence for each reported outcome was assessed as very low quality according to the GRADE assessment. This was primarily due to the small sample sizes and wide confidence intervals, which in all but one case, crossed the line of no effect. This significant uncertainty surrounding most of the outcomes, together with a lack of data for many other potentially important outcomes, supports the case for additional research. When assessing the standard Cochrane risk of bias domains it was noted that the included study did not provide sufficient information about study design and conduct, and as such, a number of domains were judged as unclear. Risk of bias was highest in domains relating to blinding of participants and outcome assessors which reflects the inherent difficulties of blinding in trials that test information provision. Synnot 2014 and others suggest that in addition to the standard Cochrane risk of bias domains, consumer health information interventions might also consider whether interventions are developed using a theoretical framework and if consumers are involved in intervention development (Sheridan 2011; Synnot 2014). The authors of the included study in this review published an earlier paper that reports the piloting of the interventions tested in the decision aid trials (Juraskova 2008). They reported that they included consumers in the development of the intervention and it was informed by the theoretically-based Ottawa decision support framework (O'Connor 1998). Future updates of this review may wish to consider subgroup analyses based on presence and absence of consumer involvement, and theoretically informed versus theoretical decision aids.
Potential biases in the review process
We applied standard Cochrane review methodology with the aim of minimising bias. At least two authors were involved in all critical stages of the review process. Where appropriate, we contacted authors of included and potentially eligible studies, largely to determine eligibility of interventions, and access additional data to support the published report. Several potentially eligible studies were excluded based on inability of the study authors to provide copies of the original interventions tested. However, through email discussion it often became apparent that the reported interventions were not formal decision aids or could be excluded based on the published information. Like the review by Synnot 2014, some outcomes reported in the included study were not assessed in this review because they were not prespecified outcomes, such as decisional satisfaction. Similarly, we collected only one outcome for each prespecified outcome category, and made this judgement on a hierarchy of measures (such as from validated objective measure to study specific non-validated measures). The included study reported three different measures of knowledge (two developed for use in the study with no validation data reported and one validated subjective measure (Joffe 2001)). As the authors did not specify whether they ranked the knowledge outcomes, we chose to report the more robust data collected using a validated measure. This was also the case for recruitment to the parent trial, which was also reported three ways (attitude towards parent trial (IBIS-II), intention to participate, and percentage actually enrolled), of which we chose percentage actually enrolled. Further consideration and revision of the outcomes reported in this review may be required in future updates. The biggest potential threat of bias to this review arose from the possibility that we did not identify all relevant published and unpublished studies. As part of a larger program of work, a formal survey of the Directors of UK registered Clinical Trials Units, and informal assessment of decision aid researchers through social media was conducted to determine if any work was being carried out in this area. No reports were identified. The lead researchers of those studies included in the Characteristics of ongoing studies were also asked whether they were aware of any other research in this area, of which none was reported.
Agreements and disagreements with other studies or reviews
Due to the inclusion of only one study (reporting two decision aid trials) with relatively small sample sizes, and the inconclusive findings of the review, we were unable to make clear comparisons with other studies or reviews. 
A U T H O R S ' C O N C L U S I O N S Implications for practice
There was insufficient evidence to determine if decision aids to support the informed consent process for clinical trials participants are more effective than existing approaches. The pooled findings from the included decision aid trials highlight considerable uncertainty surrounding most of the outcomes reported (knowledge, decisional conflict, anxiety, trial participation and trial attrition). There was very low quality evidence indicating that decision aids may lower levels of decisional regret. In addition, several primary outcomes (important for the decision process) identified as being of importance were not reported. These included accurate risk expectations; reaching choices that are consistent with personal values; or whether potential participants recognised that a decision needed to be made, were able to identify features of options that matter most to individuals, or were involved in the decision. Although the findings from Stacey 2014 suggest that decision aids are more effective than standard consent processes for treatment and screening, the applicability of these findings in the context of consent for clinical trials remains equivocal and requires more research.
Implications for research
The findings from this review highlight a gap in the evidence base.
More high quality RCTs of decision aids to support the informed consent process for clinical trials are needed. Evidence is needed from sufficiently powered (in terms of recruitment and analysis) trials across various trial populations (both in terms of clinical conditions, but also with regard to low literacy etc.), considering different interventions (e.g. comparison of drug versus surgery; behavioural intervention versus standard care), with measurement of relevant outcomes at appropriate time points.
The outcomes that should be assessed in future trials in this context requires further work (Gillies 2014e) but as a start could consider knowledge; decision conflict; satisfaction with the decision making process; values congruence; anxiety; and trial specific measures (recruitment and retention). Where possible, validated objective measures should be used to increase the study's validity but also to enable meaningful comparison across studies when combined in systematic reviews. In addition, due to the problems with accessing and locating interventions from published studies, researchers should make efforts for interventions (or intervention manuals) to be accessible post-publication, for example, various formats of interventions stored securely or accessible through web links in published article. This reporting and availability of interventions should also be extended to include a description of comparators, especially when describing standard or usual information.
Through both design and reporting, trialists should strive to minimise bias through and refer to the CONSORT statement and TIDieR checklist (a template for the reporting of interventions to enable better replication) for guidance on the issue (www.consortstatement.org; Hoffman 2014). Moreover, trialists should recognise the potential difficulties associated with conducting trials within trials (irrespective of focus) and ensure these are considered when designing nested RCTs (Graffy 2010). Participants This nested RCT of decision aids was set within the treatment trial component of the IBIS II breast cancer trial. The parent treatment trial included postmenopausal women who had received surgery for DCIS and were subsequently randomised to anastrozole or tamoxifen for five years. A sample of participants being approached to participate in the parent trial were first randomised to a nested RCT of a decision aid for trial participation plus standard information or standard information alone before being randomised to treatment allocation All participants were postmenopausal women recruited across sites in Australia, New Zealand and the UK 67 participants were randomised from the DCIS parent RCT; 34 were included in T1 analysis (post-decision) and 24 were included in the T2 analysis (3 month follow up):
A C K N O W L E D G E M E N T S
R E F E R E N C E S
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies
• Intervention: 19 at T1, 14 at T2
• Control: 15 at T1, 10 at T2. Of the participants included in the T1 analysis the mean age was 58.5 years (SD 3.9) in the intervention group and 58.7 years (SD 5.0) in the control group; 22 were married (15 in intervention and 7 in control); 31 had at least high school education or higher (18 in intervention and 13 in control); 20 were in managerial or professional work roles (10 in intervention and 10 in control); and 31 only spoke English (17 in intervention and 14 in control)
Interventions
The decision aid booklet was designed to include evidence-based representation of breast cancer risk, the IBIS-II trial rationale, explanation of management options available on and off the trial, a comparison of the risks and benefits of each option, and values clarification worksheets. Authors state that decision aids were designed to meet IPDAS guidelines for content development. Intervention group received the standard parent RCT information sheet (no details given in publication as to content) and the decision aid booklet • Knowledge about clinical trials generally and the IBIS-II trial specifically (study specific measures (7-item general knowledge and 12 (prevention) and 16 (DCIS) objective understanding; and QuIC Part B, a 14 item measure);
• Attitudes toward participating in the trial (a 9-item scale adapted from attitude scale);
• Anxiety (using 6-item short form State-Trait Anxiety Inventory (STAI) scale). At T2 (3 month follow-up)
• Decisional satisfaction (using the 6-item Satisfaction with Decision (SWD) scale);
• Decisional regret (a 5-item Decisional Regret Scale);
• Intention to participate;
• Actual enrolment;
• Drop-out at end of trial.
Notes
This study was supported by Susan G. Komen for the Cure (grant number BCTR0503961) and discretionary funding from the Breast Cancer Institute of Australia, which is the fundraising and education department of the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG; no grant number)
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk Randomisation sequence was generated using a web-based random number generator (www.randomizer.org). Randomisation was performed in blocks of 10 according to centre Allocation concealment (selection bias) Low risk Pre-randomised, sequentially numbered, sealed envelopes were provided Incomplete outcome data (attrition bias) All outcomes
High risk
The authors report that there were no differences (in terms of rates and reasons) for drop out in both arms. However, 66 participants (23% of those randomised) were not included in the analysis due to previous participation in a clinical trial which may result in ceiling effects for several of the measures. This was a post-randomisation decision 
